Prospective Safety Surveillance of GH-Deficient Adults: Comparison of GH-Treated vs Untreated Patients
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
CONTEXT: In clinical practice, the safety profile of GH replacement therapy for GH-deficient adults compared with no replacement therapy is unknown. OBJECTIVE: The objective of this study was to compare adverse events (AEs) in GH-deficient adults who were GH-treated with those in GH-deficient adults who did not receive GH replacement. DESIGN AND SETTING: This was a prospective observational study in the setting of US clinical practices. PATIENTS AND OUTCOME MEASURES: AEs were compared between GH-treated (n = 1988) and untreated (n = 442) GH-deficient adults after adjusting for baseline group differences and controlling the false discovery rate. The standardized mortality ratio was calculated using US mortality rates. RESULTS: After a mean follow-up of 2.3 years, there was no significant difference in rates of death, cancer, intracranial tumor growth or recurrence, diabetes, or cardiovascular events in GH-treated compared with untreated patients. The standardized mortality ratio was not increased in either group. Unexpected AEs (GH-treated vs untreated, P ≤ .05) included insomnia (6.4% vs 2.7%), dyspnea (4.2% vs 2.0%), anxiety (3.4% vs 0.9%), sleep apnea (3.3% vs 0.9%), and decreased libido (2.1% vs 0.2%). Some of these AEs were related to baseline risk factors (including obesity and cardiopulmonary disease), higher GH dose, or concomitant GH side effects. CONCLUSIONS: In GH-deficient adults, there was no evidence for a GH treatment effect on death, cancer, intracranial tumor recurrence, diabetes, or cardiovascular events, although the follow-up period was of insufficient duration to be conclusive for these long-term events. The identification of unexpected GH-related AEs reinforces the fact that patient selection and GH dose titration are important to ensure safety of adult GH replacement.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reducing Bias in Observational Studies Using Subclassification on the Propensity Score
Rosenbaum, P. R., & Rubin, D. B. (1984) · Journal of the American Statistical Association · doi:10.1080/01621459.1984.10478078 · Cited by 3,082
Molitch, M. E., Clemmons, D. R., Malozowski, S., Merriam, G. R., & Vance, M. L. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0179 · Cited by 1,047
Nonspecific medication side effects and the nocebo phenomenon
Barsky, A. J. (2002) · JAMA · doi:10.1001/jama.287.5.622 · Cited by 784 · cited 1×
“The latter, termed the nocebo phenomenon, occurs commonly when patients starting new medications have had AEs with other drugs or have preexisting symptoms that predispose them to attribute new or worsening events to the medication (35).”
BackgroundMortality in Patients with Pituitary Disease
Sherlock, M., Ayuk, J., Tomlinson, J. W., Toogood, A. A., Aragon-Alonso, A., Sheppard, M. C., Bates, A. S., & Stewart, P. M. (2010) · Endocrine Reviews · doi:10.1210/er.2009-0033 · Cited by 392
Long-term mortality in the United States cohort of pituitary-derived growth hormone recipients
Mills, J. L., Schonberger, L. B., Wysowski, D. K., Brown, P., Durako, S. J., Cox, C., Kong, F., & Fradkin, J. E. (2004) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2003.12.036 · Cited by 118
Cited by
Yuen, K. C. J., Biller, B. M. K., Radovick, S., Carmichael, J. D., Jasim, S., Pantalone, K. M., & Hoffman, A. R. (2019) · Endocrine Practice · doi:10.4158/gl-2019-0405 · Cited by 298
Higham, C. E., Johannsson, G., & Shalet, S. M. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30053-8 · Cited by 267
Effects of growth hormone on glucose metabolism and insulin resistance in human
Kim, S.-H., & Park, M.-J. (2017) · Annals of Pediatric Endocrinology & Metabolism · doi:10.6065/apem.2017.22.3.145 · Cited by 181
Cancer risks in patients treated with growth hormone in childhood: the SAGhE European cohort study
Swerdlow, A. J., Cooke, R., Beckers, D., Borgström, B., Butler, G., Carel, J.-C., Cianfarani, S., Clayton, P., Coste, J., Deodati, A., et al. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2046 · Cited by 153
“The large postmarketing surveillance studies (10 – 12, 14, 16) have also depended on active reporting of cancers to the pharmaceutical company by physicians, the completeness of which is unknown, especially after patients leave pediatric endocrine care.”
BackgroundBoguszewski, M. C. S., Boguszewski, C. L., Chemaitilly, W., Cohen, L. E., Gebauer, J., Higham, C., Hoffman, A. R., Polak, M., Yuen, K. C. J., Alos, N., et al. (2022) · European Journal of Endocrinology · doi:10.1530/eje-21-1186 · Cited by 117
Self-citationIdiopathic adult growth hormone deficiency
Melmed, S. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-4012 · Cited by 58
Self-citationChild, C. J., Conroy, D., Zimmermann, A. G., Woodmansee, W. W., Erfurth, E. M., & Robison, L. L. (2015) · European Journal of Endocrinology · doi:10.1530/eje-14-1123 · Cited by 58
Self-citationvan Varsseveld, N. C., van Bunderen, C. C., Franken, A. A. M., Koppeschaar, H. P. F., van der Lely, A. J., & Drent, M. L. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1764 · Cited by 26
Metadata
- Authors
- Hartman, M. L., Xu, R., Crowe, B. J., Robison, L. L., Erfurth, E. M., Kleinberg, D. L., Zimmermann, A. G., Woodmansee, W. W., Cutler, G. B., Chipman, J. J., Melmed, S., & on behalf of the International HypoCCS Advisory Board
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2013-03-01
- Volume
- 98
- Issue
- 3
- Pages
- 980-988
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2145616516
- Cited by
- 88
- References
- 5
- FWCI
- 8.25
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.